---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-056482"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:39:55.387966+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31

## Summary
- Offering of 19.73M shares at $17.75/share plus 1.4M pre-funded warrants at $17.749/warrant.
- Underwriters exercised overallotment option for 3.17M additional shares in full on May 6.
- Net proceeds estimated at $405M; proceeds to fund clinical development of abdakibart through Phase 3 topline data.
- Preliminary cash, cash equivalents and short-term investments as of March 31, 2026: $82.0M.
- Expected closing May 7, 2026; cash runway expected to extend into 2029.

## SEC filing metadata
- accession: 0001104659-26-056482
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-056482
- JSON: https://secwatch.observer/filing/0001104659-26-056482.json
- Plain text: https://secwatch.observer/filing/0001104659-26-056482.txt

## Source-grounded claims
- claim_id: 5ba31f299d1dd6f13418d9f3a2c94826d8bd6953
  claim: Avalo Therapeutics, Inc. reported preliminary financial results for the quarter ended March 31, 2026.
  evidence_excerpt: As of March 31, 2026, the Company estimates that it had cash, cash equivalents and short-term investments of approximately $82.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm
- claim_id: 5017dedfebbbe0fd89fb565e87d18f72f53e9ba3
  claim: Avalo Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters valued at approximately $405.0 million (effective 2026-05-05).
  evidence_excerpt: On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a price to the public of $17.75 per Share, and (b) pre-funded warrants to purchase up to 1,400,000 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $17.749 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.